Leon P. Pybus
Leon P. Pybus publishes mostly in Molecular Biology, Biomedical Engineering and Radiology, Nuclear Medicine and Imaging, on topics such as Viral Infectious Diseases and Gene Expression in Insects, Protein purification and stability and Monoclonal and Polyclonal Antibodies Research.
- World rank
- #2,809,856 of 7,710,434 ranked researchers
- Rank in United Kingdom
- #194,295 of 367,258
- Works
- 25
- Citations
- 523
- Citations per work
- 20.9
What does Leon P. Pybus research?
Leon P. Pybus's work is mostly in Biochemistry, Genetics and Molecular Biology (69%), Engineering (13%), Medicine (12%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences1768.7%
- Physical Sciences313.4%
- Engineering313.4%
- Health Sciences312.0%
- Medicine312.0%
- Everything else15.9%
- 1Molecular Biology60% of their works
- 2Biomedical Engineering13% of their works
- 3Radiology, Nuclear Medicine and Imaging9% of their works
- 4Genetics4% of their works
- 5Biotechnology4% of their works
- 6Oncology3% of their works
Research topics
- Viral Infectious Diseases and Gene Expression in Insects
- Protein purification and stability
- Monoclonal and Polyclonal Antibodies Research
- 3D Printing in Biomedical Research
- Cancer Research and Treatments
- Virus-based gene therapy research
- Microbial Metabolic Engineering and Bioproduction
- Innovative Microfluidic and Catalytic Techniques Innovation
Which keywords describe Leon P. Pybus's research?
The keywords of their largest research topics: Glycosylation, Cell Culture, Mammalian Cells, Recombinant Protein, Monoclonal Antibodies, Therapeutic Antibodies, Biopharmaceuticals and Protein Aggregation.
- Tumor Targeting
- Metabolic Engineering
- Droplet Formation
- AAV
- Tissue Engineering
- Fc Receptors
- Protein Aggregation
- Therapeutic Antibodies
- Recombinant Protein
- Cell Culture
- Glycosylation
- Mammalian Cells
- Monoclonal Antibodies
- Biopharmaceuticals
- Antibody Engineering
- Bioprinting
- Gene Therapy
- Bacterial Therapy
- Genome-Scale Models
- Microfluidics
- Viral Vectors
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Glycosylation262 topics
- Cell Culture252 topics
- Mammalian Cells201 topic
- Recombinant Protein201 topic
- Monoclonal Antibodies152 topics
- Therapeutic Antibodies152 topics
- Biopharmaceuticals91 topic
- Protein Aggregation91 topic
- Antibody Engineering61 topic
- Fc Receptors61 topic
- Bioprinting51 topic
- Tissue Engineering51 topic
- Gene Therapy42 topics
- AAV21 topic
- Bacterial Therapy21 topic
- Droplet Formation21 topic
- Genome-Scale Models21 topic
- Metabolic Engineering21 topic
- Microfluidics21 topic
- Tumor Targeting21 topic
- Viral Vectors21 topic
Where does Leon P. Pybus work?
Leon P. Pybus's main affiliation in the publication record is Fujifilm (United Kingdom), United Kingdom.
How many publications and citations does Leon P. Pybus have?
OpenAlex counts 25 works and 523 citations for Leon P. Pybus, an h-index of 11, ranking #2,809,856 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Leon P. Pybus. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.